

October 1, 2020

Stayble's pre-clinical data and the clinical phase 1b study on STA363 is published in the journal SPINE

A scientific article based on pre-clinical studies and the clinical phase 1b study with STA363 has been published in the highly prestigious scientific journal Spine.

"It is crucial to have external validation of our research and pharmaceutical development. The publication of clinical study results in one of the most highly ranked journals within our field, Spine, reflects the high level of interest in STA363 and marks a milestone for the company," says Anders Lehmann, VP Development, Stayble.

The scientific article presents Stayble's pre-clinical and early stage clinical research, concluding that STA363 induces proliferation of connective tissue in the intervertebral disc and that the treatment is safe and tolerable. Spine is an internationally leading journal in research regarding spinal disorders.

CEO Andreas Gerward comments: "Spine is the leading journal within our field. We could not have received a better seal of quality on our research. This will be an important part factor when we engage in upcoming discussions with Key Opinion Leaders and future partners."

The article: Olmarker; Gerward, Isberg, Lehmann, Berg - Translational Studies on Biologic Fusion of a Vertebral Segment as a Novel Treatment Modality for Low Back Pain, SPINE (2020). doi: 10.1097/BRS.0000000000003699. Online ahead of print.

Link to Spine: <https://journals.lww.com/spinejournal>.

For additional information

Andreas Gerward, CEO of Stayble Therapeutics AB
andreas.gerward@stayble.se, +46 (0)730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient's life and to require minimal rehabilitation. The Company's focus is set upon the continued clinical development, and is currently conducting a clinical phase 2b study is underway. Stayble's vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company's Certified Adviser and can be reached at +46 (0)8 5030 1550 or e-mail ca@mangold.se.